During the coronavirus disease 2019 (COVID-19) pandemic, patients are more likely to have delayed cancer screenings rather than their doctors and clinics.
Nearly 24% of patients with cancer delayed screenings because of the coronavirus disease 2019 (COVID-19) pandemic, according to a recently released American Society of Clinical Oncology (ASCO) survey of 1142 individuals with current or past cancer diagnoses. The survey included 4012 individuals overall, including caregivers and family members.
Among those who delayed screenings, the patient made the decision to cancel or delay a screening two-thirds of the time; 63% of patients who delayed or skipped screenings reported being concerned about these delays, ASCO said.
The survey addressed not only COVID-19 issues but also perceptions of how an individual’s race affects access to the best quality cancer care. ASCO said 59% of those surveyed agreed racism affects the quality of care an individual receives in the US health care system, 53% said Black Americans are less likely to have access to the same quality of cancer care as White Americans, and 19% said race affects a person’s likelihood of surviving cancer.
Non-White respondents were more likely to agree that race affects quality of care in the United States (Black, 76%; Hispanic, 70%; Asian, 66%; White, 53%), and Black adults are more likely than White adults to have not been scheduled for any cancer screening appointments during the COVID-19 pandemic (68% vs 61%).
Clinical Trial Perceptions
The survey findings indicated 75% of respondents would be willing to participate in a clinical trial for cancer treatment if they had cancer; however, just 53% said they are knowledgeable about clinical trials, and 48% said they believe patients with cancer who participate in clinical trials do not receive the best possible care and “are just part of an experiment.”
Among patients with cancer who have limited their contact with others to avoid contracting COVID-19, 84% were White and 73% were Black. The survey said 49% of patients with cancer have made “a lot of sacrifices” in their daily living because of their higher risk for contracting COVID-19, with more Blacks indicating so than Whites (61% vs 47%).
Many also indicated they have not had enough emotional support (33%) or help (22%), such as for picking up medications, during the pandemic.
ASCO said two-thirds of family members and caregivers would like to do more to support their loved ones with cancer in both practical and emotional ways.
The types of effects on cancer care caused by the pandemic reported by those with current or past cancer included delayed visits (16%), doctor consultations made via telehealth instead of in person (15%), cancer monitoring tests delayed (12%), health coverage lost (2%), treatment such as surgery or radiation cancelled (2%), and treatment regimens changed (1%). ASCO said 68% reported no effects on cancer care as a result of COVID-19.
Click here for results of the 2019 ASCO survey.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.